Search research articles
Contact Us
Filters
Showing results (41-50 of 118) with videos related to
Page
of 12
Sort By:
Health Economics
|
July 28, 2021
Does public long-term care expenditure improve care-related quality of life of service users in England?
Francesco Longo, Karl Claxton, James Lomas, et al.
Intensive Care Medicine
|
May 25, 2002
Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis
Elisabeth Fenwick, Jonathan Wilson, Mark Sculpher, et al.
Gates Open Research
|
May 15, 2020
Value-based tiered pricing for universal health coverage: an idea worth revisiting
Kalipso Chalkidou, Karl Claxton, Rachel Silverman, et al.
Health Economics
|
August 3, 2021
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems
Beth Woods, Aimée Fox, Mark Sculpher, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
May 23, 2020
Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts
Marta O Soares, Mark J Sculpher, Karl Claxton
International Journal of Technology Assessment in Health Care
|
June 21, 2007
Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al
Christopher McCabe, Aki Tsuchiya, Karl Claxton, et al.
Health Affairs (Project Hope)
|
January 14, 2005
When is evidence sufficient?
Karl Claxton, Joshua T Cohen, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 19, 2016
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods, Paul Revill, Mark Sculpher, et al.
Health Policy (Amsterdam, Netherlands)
|
April 2, 2023
The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17
Stephen Martin, Karl Claxton, James Lomas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 15, 2006
Probabilistic analysis and computationally expensive models: Necessary and required?
Susan Griffin, Karl Claxton, Neil Hawkins, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 118) with videos related to
Sort By:
Page
of 12
Health Economics
|
July 28, 2021
Does public long-term care expenditure improve care-related quality of life of service users in England?
Francesco Longo, Karl Claxton, James Lomas, et al.
Intensive Care Medicine
|
May 25, 2002
Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis
Elisabeth Fenwick, Jonathan Wilson, Mark Sculpher, et al.
Gates Open Research
|
May 15, 2020
Value-based tiered pricing for universal health coverage: an idea worth revisiting
Kalipso Chalkidou, Karl Claxton, Rachel Silverman, et al.
Health Economics
|
August 3, 2021
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems
Beth Woods, Aimée Fox, Mark Sculpher, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
May 23, 2020
Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts
Marta O Soares, Mark J Sculpher, Karl Claxton
International Journal of Technology Assessment in Health Care
|
June 21, 2007
Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al
Christopher McCabe, Aki Tsuchiya, Karl Claxton, et al.
Health Affairs (Project Hope)
|
January 14, 2005
When is evidence sufficient?
Karl Claxton, Joshua T Cohen, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 19, 2016
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods, Paul Revill, Mark Sculpher, et al.
Health Policy (Amsterdam, Netherlands)
|
April 2, 2023
The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17
Stephen Martin, Karl Claxton, James Lomas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 15, 2006
Probabilistic analysis and computationally expensive models: Necessary and required?
Susan Griffin, Karl Claxton, Neil Hawkins, et al.
Page
of 12